NO20014103L - N-[2-hydroksy-3-(1-piperidinyl)propoksy]pyridin-1-oksid-3- karboksimidoylklorid og dets anvendelse for behandling avinsulinresistens - Google Patents

N-[2-hydroksy-3-(1-piperidinyl)propoksy]pyridin-1-oksid-3- karboksimidoylklorid og dets anvendelse for behandling avinsulinresistens

Info

Publication number
NO20014103L
NO20014103L NO20014103A NO20014103A NO20014103L NO 20014103 L NO20014103 L NO 20014103L NO 20014103 A NO20014103 A NO 20014103A NO 20014103 A NO20014103 A NO 20014103A NO 20014103 L NO20014103 L NO 20014103L
Authority
NO
Norway
Prior art keywords
insulin resistance
piperidinyl
propoxy
pyridine
hydroxy
Prior art date
Application number
NO20014103A
Other languages
English (en)
Other versions
NO20014103D0 (no
NO319793B1 (no
Inventor
Maria Kuerthy
Katalin Biro
Karoly Nagy
Laszlo Ueroegdi
Zita Csakai
Jenoe Szilbereky
Tamas Mogyorosi
Magdolna Toeroek
Andras Komaromi
Ede Marvanyos
Mihaly Barabas
Mihalyne Kardos
Zoltan Nagy
Laszlo Koranyi
Melinda Nagy
Original Assignee
Biorex Kutato Fejlesztoe Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejlesztoe Kft filed Critical Biorex Kutato Fejlesztoe Kft
Publication of NO20014103D0 publication Critical patent/NO20014103D0/no
Publication of NO20014103L publication Critical patent/NO20014103L/no
Publication of NO319793B1 publication Critical patent/NO319793B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20014103A 1999-02-26 2001-08-23 N-[2-hydroksy-3-(1-piperidinyl)propoksy]pyridin-1-oksid-3-karboksimidoylklorid og dets anvendelse til fremstilling av et farmasoytisk preparat, samt farmasoytisk preparat. NO319793B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PCT/HU2000/000015 WO2000050403A1 (en) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Publications (3)

Publication Number Publication Date
NO20014103D0 NO20014103D0 (no) 2001-08-23
NO20014103L true NO20014103L (no) 2001-10-22
NO319793B1 NO319793B1 (no) 2005-09-12

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014103A NO319793B1 (no) 1999-02-26 2001-08-23 N-[2-hydroksy-3-(1-piperidinyl)propoksy]pyridin-1-oksid-3-karboksimidoylklorid og dets anvendelse til fremstilling av et farmasoytisk preparat, samt farmasoytisk preparat.

Country Status (27)

Country Link
US (1) US6649628B1 (no)
EP (1) EP1163224B1 (no)
JP (1) JP4689838B2 (no)
KR (1) KR100676124B1 (no)
AT (1) ATE237590T1 (no)
AU (1) AU779096B2 (no)
BG (1) BG65178B1 (no)
BR (1) BR0008969A (no)
CA (1) CA2360451C (no)
CZ (1) CZ297386B6 (no)
DE (1) DE60002187T2 (no)
DK (1) DK1163224T3 (no)
EE (1) EE04961B1 (no)
ES (1) ES2193055T3 (no)
HR (1) HRP20010584B1 (no)
HU (1) HUP9900475D0 (no)
IL (2) IL144866A0 (no)
NO (1) NO319793B1 (no)
PL (1) PL197692B1 (no)
PT (1) PT1163224E (no)
RS (1) RS50083B (no)
RU (1) RU2250901C2 (no)
SI (1) SI1163224T1 (no)
SK (1) SK287063B6 (no)
UA (1) UA72495C2 (no)
WO (1) WO2000050403A1 (no)
ZA (1) ZA200106488B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
BR0306778A (pt) * 2002-01-11 2004-12-28 Biorex Kutato Fejlesztoe Kft Derivados de carboxamidina e seu uso no tratamento de doenças vasculares
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
WO2008039514A1 (en) * 2006-09-26 2008-04-03 Cytrx Corporation Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
BRPI0914684C1 (pt) 2008-06-26 2021-05-25 Orphazyme As uso de hsp70 ou um fragmento funcional ou variante do mesmo, e, hsp70 ou um fragmento funcional ou variante do mesmo
CN102215842A (zh) 2008-11-18 2011-10-12 参天制药株式会社 含有吡啶-3-甲醛o-(哌啶-1-基-丙基)-肟衍生物作为有效成分的脉络膜视网膜变性疾病的治疗剂
WO2012072082A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
ES2691981T3 (es) * 2012-09-06 2018-11-29 Mcpharma Biotech Inc. Tratamiento de la diarrea y de la diarrea post-destete con almidón resistente de patata
KR101768784B1 (ko) 2012-09-14 2017-08-16 쌩-고벵 글래스 프랑스 전기 접속 요소를 갖는 판유리
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
PL3193840T3 (pl) * 2014-09-15 2021-12-06 Orphazyme A/S Preparat arimoklomolu
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
HUE052158T2 (hu) 2016-04-29 2021-04-28 Orphazyme As Arimoklomol a glükocerebroszidázzal társult rendellenességek kezeléséhez
US20200085812A1 (en) 2017-05-24 2020-03-19 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
MX2020012480A (es) 2018-05-28 2021-03-25 Orphazyme As Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
MX2023000033A (es) 2020-06-24 2023-04-10 Kempharm Denmark As Arimoclomol para tratar la enfermedad de gaucher.
CA3202568A1 (en) * 2020-11-19 2022-05-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
CA3205873A1 (en) 2020-12-24 2022-06-30 Zevra Denmark A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
AU3182400A (en) 2000-09-14
UA72495C2 (uk) 2005-03-15
BG65178B1 (bg) 2007-05-31
NO20014103D0 (no) 2001-08-23
PL350915A1 (en) 2003-02-10
JP2002537384A (ja) 2002-11-05
CA2360451C (en) 2011-01-04
DE60002187D1 (de) 2003-05-22
JP4689838B2 (ja) 2011-05-25
YU60301A (sh) 2004-05-12
KR20010102410A (ko) 2001-11-15
DE60002187T2 (de) 2003-12-11
BG105837A (en) 2002-03-29
WO2000050403A1 (en) 2000-08-31
BR0008969A (pt) 2001-11-27
NO319793B1 (no) 2005-09-12
CZ297386B6 (cs) 2006-11-15
KR100676124B1 (ko) 2007-01-31
EP1163224B1 (en) 2003-04-16
SI1163224T1 (en) 2003-08-31
HRP20010584A2 (en) 2002-08-31
RS50083B (sr) 2009-01-22
ATE237590T1 (de) 2003-05-15
IL144866A0 (en) 2002-06-30
IL144866A (en) 2007-07-04
EP1163224A1 (en) 2001-12-19
ES2193055T3 (es) 2003-11-01
PL197692B1 (pl) 2008-04-30
CA2360451A1 (en) 2000-08-31
EE200100447A (et) 2002-12-16
AU779096B2 (en) 2005-01-06
RU2250901C2 (ru) 2005-04-27
CZ20013053A3 (cs) 2002-01-16
SK287063B6 (sk) 2009-10-07
HUP9900475D0 (en) 1999-04-28
PT1163224E (pt) 2003-07-31
DK1163224T3 (da) 2003-08-04
EE04961B1 (et) 2008-02-15
US6649628B1 (en) 2003-11-18
HRP20010584B1 (en) 2010-08-31
ZA200106488B (en) 2002-08-07
SK11582001A3 (sk) 2001-12-03

Similar Documents

Publication Publication Date Title
NO20014103L (no) N-[2-hydroksy-3-(1-piperidinyl)propoksy]pyridin-1-oksid-3- karboksimidoylklorid og dets anvendelse for behandling avinsulinresistens
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
EA200101166A1 (ru) Ингибиторы металлопротеаз
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
TW229205B (no)
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
MY106315A (en) Pharmaceutical agents
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
GEP20053631B (en) ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
AP2000001934A0 (en) Antipicornaviral compounds, their preparation and use.
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
ATE234615T1 (de) Verwendung von acetylcystein zur herstellung eines arzneimittels zur behandlung von chronischen geschwüren
MEP5908A (xx) Upotreba enantiomerno čistog escitaloprama
DE69531098D1 (de) Piperidine und pyrrolidine
SE0102147D0 (sv) New methods
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
MA27649A1 (fr) Derives d'acylphenyluree substitues par carbonylamino, methode de production et d'utilisation de ceux-ci.
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
TR200101980T2 (tr) Arilalkanoil türevleri, bunların preparasyon işlemleri
DK1232173T3 (da) Nye fusidinsyrederivater
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees